Cerebral beta-amyloidosis, one of the pathological hallmarks of Alzheimer's disease (AD), elicits a wellcharacterised, microglia-mediated local innate immune response. In contrast, it is not clear whether cells of the adaptive immune system, in particular T-cells, react to cerebral amyloidosis in AD. Even though parenchymal T-cells have been described in post-mortem brains of AD patients, it is not known whether infiltrating T-cells are specifically recruited to the extracellular deposits of beta-amyloid, and whether they are locally activated into proliferating, effector cells upon interaction with antigen-presenting cells (APCs). To address these issues we have analysed by confocal microscopy and flow-cytometry the localisation and activation status of both T-cells and APCs in transgenic (tg) mice models of AD-like cerebral amyloidosis. Increased numbers of infiltrating T-cells were found in amyloid-burdened brain regions of tg mice, with concomitant up-regulation of endothelial adhesion molecules ICAM-1 and VCAM-1, compared to non-tg littermates. The infiltrating T-cells in tg brains did not co-localise with amyloid plaques, produced less interferon-gamma than those in controls and did not proliferate locally. Bona-fide dendritic cells were virtually absent from the brain parenchyma of both non-tg and tg mice, and APCs from tg brains showed an immature phenotype, with accumulation of MHC-II in intracellular compartments. These results indicate that cerebral amyloidosis promotes T-cell infiltration but interferes with local antigen presentation and T-cell activation. The inability of the brain immune surveillance to orchestrate a protective immune response to amyloid-beta peptide might contribute to the accumulation of amyloid in the progression of the disease.
Introduction
T-cells constantly patrol body tissues as part of the physiological process of immune surveillance (von Andrian and Mackay, 2000) . Upon recognition of their cognate antigen exposed on mature antigen-presenting cells (APCs), T-cells undergo activation, proliferate and exert effector functions, such as cytotoxicity in the case of CD8 + T-cells and activation of macrophages and antibodyproducing B cells in the case of CD4 + T-helper cells. In the CNS, physiological immune surveillance is mediated by patrolling Tcells and mature APCs found in the perivascular and meningeal spaces, and at the blood-cerebrospinal fluid (CSF) barrier of the choroid plexus (CP) (Ransohoff et al., 2003; Ousman and Kubes, 2012) . In contrast to CSF-associated patrolling T-cells, T-cells retained in the brain parenchyma often reflect an on-going pathology. In autoimmune conditions such as multiple sclerosis, autoreactive T-cells play a causative role in fostering macrophage-mediated demyelination (Ciccarelli et al., 2014) . In Alzheimer's disease (AD)-related neurodegeneration, characterised by the accumulation of intracellular aggregates of abnormally phosphorylated tau and extracellular deposition of aggregated amyloid-beta peptide (Ab) (Selkoe, 2011) , the role of the immune system is less well understood (Town, 2010) .
While several studies have demonstrated the presence of CD4 + and CD8 + T-cells in post-mortem brains of AD patients (Rogers et al., matter of debate. It is not clear whether T-cells are specifically recruited to amyloid deposits in AD brains, and very little is known on their activation status. Activated IFN-c producing-T-cells could promote macrophage and microglia receptor-mediated phagocytosis (Schroder et al., 2004) , thus supporting beneficial clearance of extracellular amyloid. On the other hand, overt T-cell activation could result in direct cytotoxicity and macrophage-mediated tissue damage, thereby contributing to neuronal demise (Aloisi et al., 2000b) . Hence, the activation state of the infiltrating T-cells might be disease-relevant.
To elucidate this issue we have analysed T-cell numbers, localisation and phenotype in transgenic (tg) mouse models of AD-like cerebral amyloidosis. We show that cerebral amyloidosis is associated with brain infiltration of T-cells, which do not co-localise with amyloid deposits, do not proliferate locally and display low expression of the effector cytokine IFN-c.
Materials and methods

Transgenic mice
ArcAb (Knobloch et al., 2007) ; APP-PS1-dE9 (Jankowsky et al., 2004) ; Tg2576 (Hsiao et al., 1996) ; E22DAb (Kulic et al., 2012) ; recombination activating gene 2 (RAG2) knockout mice (Shinkai et al., 1992) were used. ArcAb and APP-PS1-dE9 were on a congenic C57BL/6 background; Tg2576 were on a hybrid C57BL/6 and SJL background; E22DAb were on hybrid C57BL6 and DBA/2 background. In each experiment we balanced the genders across genotypes; no gender-specific effect was noted. The mice were kept in OHB conditions, at 22°C ± 1°C and a 12 h light-dark cycle beginning at 7:00 AM. Water and food were available ad libitum. Experiments were conducted in accordance with the Swiss law for care and use of animals (''455.163 Tierversuchsverordnung" 2010) and were approved by the veterinarian authorities of the Canton of Zurich (license number 145/2014). This report adheres to the ARRIVE guidelines for animal research.
Microbiological examination
Brains from two non-tg and two tg mice (2 year-old) underwent the following microbiological examination: PCR for Lymphocytic choriomeningitis, Theiler's encephalomyelitis and mouse hepatitis viruses; bacteriology culture (performed by MicroBioS GmbH, Reinach, Switzerland).
Flow-cytometry analyses
Sacrifice and mononuclear cell-suspension preparation -Mice were sacrificed via isoflurane inhalation and quickly perfused with Ringer solution (Braun Medical, Emmenbruecke, Switzerland) . After removal of meningi, brain regions of interest were dissected on ice. Lateral, third and fourth ventricle-choroid plexus were used. Mononuclear single cell suspension was prepared according to standard protocols (Suter et al., 2003) . For cerebrum (whole brain without cerebellum and choroid plexus), minced samples were digested for 1 h at 37°C in HBSS containing 50 lg/ml DNase I and 100 lg/ml collagenase/dispase (Roche, Rotkreuz, Switzerland). The suspension was passed through a 100 lm Nylon mesh (Falcon, BD Biosciences, Bedford, MA, USA), pelleted, resuspended in 30% Percoll (Amersham, GE Healthcare, Uppsala Sweden) in HBSS and centrifuged at 15,500 rpm for 30 min at 4°C. After eliminating the myelin debris via aspiration, the mononuclear cell phase was collected. Choroid plexus samples were enzymatically digested at 37°C for 30 min, passed through a 100 lm mesh, washed and used directly. Spleens were minced in RPMI plus 5% FCS, digested with 100 lg/ml collagenase-dispase and 50 lg/ml DNaseI for 20 min at RT, passed through a 100 lm Nylon mesh, processed with ACK lysis buffer, washed in HBSS and used for staining. Surface staining -CNS-mononuclear cells and splenocytes were washed in FACS buffer (HBSS, 2% FCS, 10 mM EDTA, 0.01% NaN 3 ). After treatment with an antibody against Fc receptor (anti-mouse CD16/32, TrueStain FcX TM, BioLegend, san Diego, CA, USA), the cells were stained for 15 min at 4°C with specific antibodies, washed and analysed. Intracellular staining -Intracellular stainings were performed with the eBioscience kit (n.72-5775, San Diego, CA, USA) according to manufacturer's instructions. DC panels -In each experiment we included at least eight non-tg and eight tg mice. For the ArcAb 24-month-old experiment, a total of nine non-tg and ten ArcAb APP-tg animal were used; we analysed the cerebrum from nine tg and seven non-tg mice. Choroid plexuses were removed from nine non-tg and ten tg animals. They were pooled (two-four/ sample), yielding a final n = 3 of bulk samples/genotype. The spleens were dissected from four non-tg and four tg animals. A multicolour FACS study was performed with a BD LSR Fortessa analyzer. The panel for surface markers was: BV605-CD11c; FITC-MHCII; PE-CY5-B220; PE-CY5.5-CD45; PE-CY7-CD11b; PE-TR-CD80; APC-Cy7-CD86; APC-CD4; Alexa700-CD8a (all from eBioscience, San Diego, CA, USA). In some experiments, PE-CD11c, FITC-MHC-I and PE-MHC-II were used (from eBioscience, San Diego, CA, USA). The panel for intracellular staining was: FITC-MHCII; PE-CD11c; PE-CY5.5-CD45; APC-CD11b (all from eBioscience, San Diego, CA, USA). A fixable live-dead dye to exclude dead cells (Molecular Probes, Eugen, OR, USA) and compensation beads to set the compensation matrix (eBioscience, San Diego, CA, USA) were used. In some experiments, quantification beads were used (AccuChek Counting beads, Life Technologies, Invitrogen Corporation, MD, USA). Negative controls included isotype controls and fluorescence-minus-one stainings. Splenocytes were used as biological positive controls. T-cell panel -For 20-month-old ArcAb mice, we analysed six non-tg and seven tg mice. Whole brains and splenocytes from each mouse were stained for both surface and intracellular markers. For cytokine detection, the cells were restimulated in vitro at 37°C with PMA (10 À7 M) and ionomycin
(1 lg/ml) in the presence of GolgiPlug (BD Bioscience, Bedford, MA, USA). The panel used was: Surface: PE-CD45, Alexa700-CD8 (eBioscience, San Diego, CA, USA), APC-Cy7. (Hesske et al., 2010) and in accordance with a recently proposed classification (Guilliams et al., 2014) .
Bright-field immunohistochemistry
CD3, CD4, CD8, MHC-II -Mice were anesthetised via ketaminexylazine injection (10 ml/g bw) and quickly perfused with PBS. The brains were dissected on ice and fixed in 4% paraformaldehyde (granular, n.19210 Electron Microscopy Science) for 24 h (or 6 h for detection of CD4 and CD8) and cryoprotected in 30% sucrose.
Free-floating, 40 lm-thick sections were blocked with 10% donkey and goat sera O/N, followed by treatment with avidin biotin blocking kit (Vectorlabs, SP2001, Burlingame, CA, USA). The primary antibodies were incubated O/N at 4°C followed by 1 h incubation with 1:200 biotinylated secondary antibody in 10% sera. The ABC kit (Vector, PK6100 Standard, Burlingame, CA, USA) was used according to manufacturer's instructions. The staining was revealed using nickel-enhanced DAB (n.1855910, Thermo Fisher, Rockford, IL, USA). Haematoxylin counterstaining was performed using Mayer's hemalum solution (T865, Roth GmbH, Karlsruhe, Germany). Negative controls included omission of primary antibody and RAG2ko mouse model. Positive controls were spleen and liver tissue. VCAM1-ICAM1 -Mice were anesthetised via ketamine-xylazine injection (10 ml/g bw) and perfused with 1% paraformaldehyde in PBS, pH 7.4; their brains removed, embedded in Jung tissue freezing medium (Leica Microsystems, Nussloch, Germany) and frozen in a dry ice/isopentane bath. Cryostat sections (6 lm) were fixed in À20°C acetone and stained using a three-step immunoperoxidase staining kit (Vector).
Quantification CD3 + T-cell density
Per each animal, two whole sections corresponding to bregma À0.70 (for cortical density) and three sections corresponding to bregma À0.70, À1.94, À3.16 (for total density) were stained with anti-CD3 antibody as described above. Bright-field microscopy images were acquired using a Leica DM4000B microscope (Leica, Wetzlar, Germany) equipped with an Olympus DP71 digital camera (Olympus, Volketswil, Switzerland). The number of CD3 + Tcells was quantified in live mode using the meander tool of the newCAST module of the Visiopharm software (Visiopharm, HØrsholm, Denmark). For measurement of total CD3 + density, a region of interest (ROI) was drawn around each section. For cortical measurements, a ROI including somatosensory (S1BF, S1FL and S1HL regions), motor cortex 1 and 2 and cingulate cortex was drawn (see also Supplementary Fig. 1B ). The automatic stage was set to randomly move within the ROI, sampling 50% of the ROI area. On average, 15 images were quantified per ROI. CD3 + T-cells were counted by the experimenter blind to the origin of the samples; the numbers of counted elements and ROI size were automatically recorded by the software. Counts were normalised to the size of the respective ROI/2 and densities averaged across the sections yielding one value per animal. All samples were acquired and analysed blinded to genotype. 
Immunofluorescence on mouse tissue
The free-floating sections were blocked for 1 h at RT in 10% sera and incubated O/N with the proper primary antibody. The next day the sections were incubated with the appropriate secondary antibody for 2 h. Sudan Black B (#199664, Sigma-Aldrich, St Louis, MO, USA; 0.1% solution in 70% ethanol) was applied to eliminate lipofuscin autofluorescence. DAPI was used as counterstaining agent.
Thioflavin staining
The sections were treated with Thioflavin S (0.1% solution in 50% ethanol, T1892, Sigma-Aldrich, St Louis, MO, USA) for 5 min.
Extravasation study, correlation CD3
+ T-cells-amyloid fractional area and amyloid-CD3 + T-cell association study
Eight tg and seven non-tg ArcAb mice aged 15 months were sacrificed via isoflurane inhalation. Non-perfused brains were fixed in 4% paraformaldehyde for 12 h and cryoprotected in 30% sucrose for 30 h. Hundred micrometre-thick free-floating sections were washed in Trizma-buffered saline containing 0.2% Triton X-100 (TBS-T, pH 7.4), treated with proteinase K antigen retrieval for 10 min at 37°C, followed by immuno-blocking in 10% donkey serum in TBS-T for 1 h at RT. The sections were subsequently incubated with rat anti-mouse CD3, rabbit anti-pan laminin, and mouse anti-Ab antibody for 48 h at 4°C, followed by washing in TBS-T and incubation in fluorescently tagged secondary antibodies (donkey anti-rat-Cy3, donkey anti-rabbit-FITC, and donkey antimouse-Cy5, Jackson Immunoresearch Labs, West Grove, PA, USA) for 24 h at 4°C. Confocal microscopy images were acquired from the cortex (forelimb and barrel field somatosensory region, cingulate cortex 1 and 2, and the primary visual cortex), hippocampus (granular layer of the dentate gyrus and the cornu ammonis 1, 2, and 3), and the corpus callosum of each mouse brain using a Leica SP8 confocal microscope fitted with a 20Â objective (Leica, Wetzlar, Germany) (see also Supplementary Fig. 1B for sampling) . The acquired images of each mouse were combined in Zprojected image stacks in the ImageJ imaging software (National Institutes of Health, Bethesda, ML, USA). All samples were acquired and analysed blinded to genotype. did not fulfil these spatial distribution criteria were considered non-Ab-associated.
Antibodies immunohistochemistry
For the detection of CD3 we used the clone KT3 (rat anti-mouse, MCA 500GA, AbD Serotec, Kidlington, UK) and 145-2C11 from BD Bioscience (Armenian-hamster anti-mouse CD3, #553058, Bedford, MA, USA). Anti-CD4 and CD8 antibodies were from BD Bioscience (rat anti-mouse CD4, clone GK1.5, #553727 and rat antimouse CD8, clone 53-6.7, #553027, Bedford, MA, USA). Rabbit anti-mouse pan laminin was from Sigma-Aldrich (L9393, St Louis, MO, USA). For vascular adhesion molecules the primary antibodies employed were: rat anti-mouse VCAM1 (clone 2A11.12), rat antimouse ICAM1 (clone 25ZC7), rat anti human CD44 (clone 9B5) was used as IgG control (Enzmann et al., 2013) . For MHC-II detection we used the purified 2G9 clone from BD Bioscience (rat antimouse class I-A/I-E, #553621, Bedford, MA, USA). The clone SP6 (RM-9106-S0, Thermo Fisher, Rockford, IL, USA) was used to detect Ki67. For detection of MHC-I we used a rat anti-mouse antibody from BMA biomedicals (T2105, Augst, Switzerland). Biotinylated goat anti-mouse, -rabbit, and -Armenian hamster and donkey anti-mouse, -rabbit, -guinea-pig or -rat conjugated with Cy3 or DyeLight were from Jackson Immunoresearch Labs (West Grove, PA, USA).
Statistical analysis
Data are presented as the mean ± S.E.M. Statistical analysis was performed using the GraphPad Prism software (LaJolla, CA, USA). Two-group comparisons were performed using two-tailed Student's t-test; Welsh's correction was used in case of unequal variances. Multiple-group comparisons were performed with ANOVA or 2-way-ANOVA, using the Bonferroni post-hoc test. Alpha level to determine significance was set at p < 0.05.
Results
Increased CD3 + T-cell occurrence in ArcAb mouse brains compared to non-tg littermates
In order to study the effect of cerebral amyloidosis on T-cell infiltration of brain, we have assessed the occurrence of CD3 + Tcells via immunohistochemistry in 12-and 22-24-month-old ArcAb mice as compared to age-matched, non-tg littermates. CD3 + T-cells were only rarely observed in non-tg mice younger than 11 month-old, mostly localised at expected sites of immune surveillance such as the CP stroma and the meninges (data not shown). In contrast, aged (12-and in 22-24-month-old) non-tg mice consistently displayed CD3 + T-cell invasion in periventricular areas, in white matter bundles (such as the corpus callosum, internal and external capsulae, fimbria and fornix) and in the rostromigratorial stream (Fig. 1A) . The grey matter of aged non-tg mice was largely devoid of T-cells, with the exception of small number of cells in striatum and hippocampus. Quantification of CD3 + Tcells revealed significantly increased total CD3 + T-cell density in brains from 22-24-compared to 12-month-old non-tg mice (Fig. 1C) . As opposed to age-matched non-tg littermates, several CD3 + Tcells were present throughout the grey matter of cerebral cortex of aged ArcAb mice (Fig. 1B) . The CD3 + T-cells appeared both clustered and dispersed in the neuropil, with CD8 + being the predominant T-cell subtype. Both the total (i.e. measured in white and grey matter from the whole brain section) and the cortical (i.e. measured exclusively in grey matter of cerebral cortex) densities of brain CD3 + T-cells were found to be significantly up-regulated at 22-24-months of age in ArcAb mice compared to non-tg controls ( Fig. 1C and D) . At 12-months of age only the cortical CD3 + T-cell density was increased in ArcAb mice compared to littermate controls, suggesting a local redistribution of the cells (Fig. 1E) . Flow-cytometry analysis of ex vivo isolated mononuclear cells derived from whole brains (thus combining grey matter-and white matter-associated cells) revealed that CD8 + but not CD4 + T-cell numbers were increased in ArcAb mice, reaching significance at the 24-month-old time-point (Fig. 1E) . Importantly, no significant difference in splenic T-cell counts was found between non-tg and ArcAb mice. Hence, compared to non-tg controls, ArcAb mice harbour increased cerebral CD3 + CD8 + T-cells, which are focally accumulated in grey matter areas at 12-months of age and become wide-spread at 22-24-months of age.
CD3 + T-cells infiltrate the brain parenchyma of ArcAb mice
To determine whether the CD3 + T-cells observed in ArcAb mouse brains had migrated into the parenchyma or whether they were trapped in the perivascular space, 100-lm-thick brain sections from non-perfused 15-month-old ArcAb and non-tg littermates were double-labelled for CD3 and pan-laminin, followed by confocal imaging and 3D reconstruction ( Fig. 2A ). This allowed us to quantify in each section both infiltrating (i.e. beyond the panlaminin layer, such as cells 2-3 in Fig. 2B ) and intravascular CD3 + T-cells. Compared to non-tg littermate controls, ArcAb brains displayed significantly more infiltrating, but not intravascular, CD3
+ T-cells in all cortical areas examined, as well as in the hippocampal CA1 field and in the corpus callosum (Table 1 ). The increased numbers of infiltrating cells was not due to hyper-vascularization in ArcAb mice, since vessel density was not significantly different between genotypes (data not shown). Hence, ArcAb mice brains were invaded by CD3 + T-cells, which had crossed the glia limitans, resided in the parenchyma and closely associated with CNSresident cells such as astrocytes (GFAP staining, Fig. 2D ), neurons (NeuN staining, Fig. 2E ) and microglial/myeloid cells (Iba-1 staining, Fig. 2F ) as revealed by confocal microscopy. Furthermore, we have observed that, on average, 77% of total cortical CD3 + T-cells detected in ArcAb cerebral cortex were infiltrating, as opposed to 35% in non-tg littermate controls (Fig. 2C) , indicating a shift in the intravascular versus parenchymal T-cell pool in ArcAb brains.
Relationship between cerebral amyloidosis and CD3 + T-cells in ArcAb mice
The increased frequency of infiltrating CD3 + T-cells (Fig. 2C) suggested the presence of a T-cell attraction-and/or retentionfactor in brains from ArcAb mice. To ascertain whether cerebral beta-amyloidosis was the cause of T-cell attraction/retention, we compared the occurrence of CD3 + T-cells between several, independent amyloid-depositing tg models, and the E22DAb mice, which over-express amyloid precursor protein (APP) but harbour a pathology limited to intracellular Ab and leptomeningeal amyloidosis (Kulic et al., 2012) (Fig 3A, upper panel) . While CD3 + T-cells infiltrated the grey matter of all amyloid-depositing mouse brains (Fig. 3A , lower panel), no CD3 + T-cells were detected in the grey matter of the E22DAb mice. These results suggested that extracellular, parenchymal amyloidosis is required for T-cell invasion.
To further examine this possibility, we studied the relationship between CD3 + T-cells and 6E10-positive amyloid deposits in brains of 15-month-old ArcAb mice, which are heavily burdened by amyloid pathology consisting of both cerebral amyloid angiopathy (CAA)-and parenchymal plaques. Here, we found a significant cor- relation between CD3 + T-cell counts and the fractional amyloid area (including both parenchymal plaques and CAA) in cerebral cortex and hippocampus. (Fig. 3B , p < 0.01, Pearson's correlation analysis). However, microscopic examination revealed that only 34% of the total CD3 + T-cells detected were spatially associated with Ab, and of these Ab-associated cells, the majority (70%) accompanied CAA rather than parenchymal plaques ( Fig. 3C-E) . Taken together, these data suggest that extracellular amyloid deposition promotes T-cell infiltration; however, the effect is likely to be indirect since CD3 + T-cells are not consistently associated with amyloid deposits.
Possible mechanisms of CD3 + T-cell brain infiltration
We next sought to elucidate the mechanism of CD3 + T-cell infiltration in ArcAb mice brains. Since T-cells occasionally decorated Ab-laden vessels, we reasoned that microhemorrhages, which often accompany CAA, could be the cause of T-cell invasion. The spatial association between CD3 + T-cells and Prussian Blue (PB)-positive microhemorrhages was examined in brains from 12-and 22-month-old ArcAb via immunohistochemistry. PB-associated CD3 + T-cells were only occasionally observed in 12-month-old tg mice (in 1 out of 5 mice), while they were consistently found in 22-month-old mice (in 4 out of 5 mice, Fig. 4A lower panel) . However, the PB-associated CD3 + T-cells represented less than 2% of the total CD3 + T-cells detected (Fig. 4B) ; the remaining CD3 + T-cells resided several hundred micrometres away from PB deposits (Fig. 4A, upper panel) . Furthermore, there was no correlation between the numbers of PB deposits and CD3 + T-cells in neither 12-nor 22-month-old brains (Fig. 4C) . Similar results were obtained in the APP-PS1-dE9 and Tg2576 APP-tg models (data not shown). Thus, passive leucocyte extravasation was observed along with brain microhaemmorhages in aged ArcAb mice; however microhaemorrhaging was not likely to be the main cause of T-cell invasion.
On the other hand, infiltration of T-cells could involve endothelial cell activation via expression of endothelial cell adhesion molecules. Therefore, ICAM-1 and VCAM-1 levels were investigated by immunohistochemistry in 20-24-month-old ArcAb mice and non-tg littermate controls. Both adhesion molecules were found to be up-regulated in cortical brain areas and hippocampus of ArcAb mice compared to non-tg controls (Fig. 4D ). Examination at high magnification revealed a distinctive plaqueassociated (asterisk) and vessels immunoreactivity (including large and small vessels) in ArcAb mice (Fig. 4D inserts) . Such expression was pathology-specific, as it was not observed in age-matched non-tg littermate controls (Fig. 4D ) but was consistently found in amyloid-burdened brain areas of all APP-tg models examined (Supplementary Fig. 2B ). Furthermore, no upregulation of VCAM-1 and ICAM-1 was detected in the lowpathology cerebellum of the same mice ( Supplementary  Fig. 2A ), which is also devoid of T-cell infiltration ( Supplementary  Fig. 1A ). These results suggest that endothelial activation drives CD3 + T-cell infiltration in APP-tg mice brains. ⁄ GrDG = granular layer of the dentate gyrus, CA1, 2, and 3 = corpus ammonis 1, 2, and 3, resp., Corp call = corpus callosum, S1FL = somatosensory cortex, front leg, S1BF = somatosensory cortex, barrel field, Cg1, Cg2 = cingulate cortex 1 and 2, V1 = visual cortex 1. * p < 0.05; ** p < 0.01, Mann-Whitney t-test (compared to non-tg).
CD4 + and CD8 + T-cells from ArcAb mice show low proliferative activity and low IFN-c expression
Having detected numerous infiltrating CD3 + T-cells in brains of
ArcAb mice, we asked whether these cells were proliferating locally into effector, IFN-c-producing cells. CD3 + T-cells from 12- (Fig. 5A ) and 24-month-old (Fig. 5B) ArcAb mice did not show detectable expression of the proliferation marker Ki67 via confocal microscopy, even when clustered around parenchymal amyloid plaques (Fig. 5A) . The Ki67 proliferating cells observed were mostly myeloid, CD68-positive cells (data not shown). The expression levels of Ki67 were further investigated via flow-cytometry on ex-vivo isolated CD4 + and CD8 + T-cells from 20-to 24-month-old mice; no increase in either the frequency of Ki67-expressing cells or their fluorescence intensity in the Ki67 channel was observed in ArcAb mice compared to non-tg littermates (Fig. 5C ). Next, we analysed via flow-cytometry the production of the effector cytokine IFN-c by brain-derived CD4 + and CD8 + T-cells from 20 month-old ArcAb and non-tg littermates. We observed a decreased percentage of IFN-c producing cells in ArcAb mice, both in the CD4 + and CD8 + T-cell subsets ( Fig. 5D and E) . The proportional decrease in IFN-c-producing cells was due to an increase in the absolute numbers of the IFN-c-negative population (Fig. 5F ). Furthermore, IFN-c expressing cells from ArcAb mice showed lower fluorescence intensity (FI) in the IFN-c channel, indicating lower levels of expression compared to littermate controls (Fig. 5G) . The frequency and absolute numbers of CD4 + and CD8 + T-cells expressing IL-10, IL-17 and FoxP3 did not differ across the genotypes ( Supplementary Fig. 5 ) and no significant differences in IFN-c-producing cells were found in spleens of ArcAb mice compared to littermate controls (Fig. 5H) . Decreased frequency of IFN-
c-expressing brain-derived CD4
+ and CD8 + T-cells was also observed in the APP-PS1-dE9 model of AD-like amyloidosis (Supplementary Fig. 3B ). Hence, infiltrating T-cells did not proliferate locally and did not display an effector phenotype in ArcAb brains, suggesting low activation state in the presence of cerebral amyloidosis. 
Antigen-presenting cells in ArcAb brains show an immature phenotype
T-cell activation depends on antigen-presentation by the MHC class I (MHC-I) and MHC class II (MHC-II) molecules at the surface of mature APCs, such as dendritic cells (DCs) (Banchereau and Steinman, 1998) . In contrast to mature APCs, which express high surface levels of MHC-II and are potent inducers of T-cell priming and activation, immature APCs -characterised by low surface levels of MHC-II expression and accumulation of MHC-II within intracel- lular compartments-are mostly tolerogenic (for a review: (Lutz and Schuler, 2002) ). We therefore analysed MHC-II surface expression by flow-cytometry on ex-vivo isolated mononuclear cells derived from cerebra of 20 month-old ArcAb and non-tg littermates (Fig. 6 ). Since B cells were virtually undetectable in brains of both genotypes, we focused on cells of the myeloid lineage. To distinguish resident microglia from other periphery-derived myeloid cells, we have taken advantage of their well-known differential surface expression of the markers CD45 and CD11b (Prinz et al., 2011; Greter et al., 2015) . This approach allowed us to clearly identify microglial cells (CD11b   +   CD45   int ) and periphery-derived CNS ''myeloid cells" (CD11b   +   CD45 hi , e.g. perivascular and leptomeningeal DCs and macrophages, Fig. 6A ). The frequency of both myeloid populations was significantly increased in the ArcAb mice ( Fig. 6A and C) , with signs of microglial activation (increased expression of CD45 and CD11c, Fig. 6D (Fig. 6B ), in agreement with the notion of microglial cells being immature APCs (Carson et al., 1998; Aloisi et al., 2000a) . In contrast, cerebrum-derived DCs, even though rare, expressed high levels of MHC-II (Fig. 6B) , consistent with the known mature APCs phenotype of perivascular and letpomeningeal DCs (Colton, 2013) . ArcAb cerebra harboured an overall increased frequency of MHC-II + microglial cells and DCs compared to non-tg littermates (Fig. 6E) .
However, the MHC-II fluorescence intensity was significantly lower in ArcAb samples compared to controls (Fig. 6F ). In fact, only the proportion of MHC-II int microglia and MHC-II int DCs was increased in ArcAb mice samples (Fig. 6G ). On the other hand, the frequency of MHC-II hi cells was decreased in ArcAb samples (as in the case of microglial cells) or unchanged (in the DCs subset) compared to non-tg littermate controls (Fig. 6G) . No increase in CD80 and CD86, co-stimulatory molecules required for T-cell activation, was observed in brain-derived APCs from ArcAb samples (Supplementary Fig. 4B-D) . Unchanged MHC-II hi cells (frequency and absolute numbers of both microglial and DCs) and increased frequency of MHC-II int were observed also in the APP-PS1-dE9 model of AD-like amyloidosis ( Supplementary Fig. 3E -I and Supplementary Table 1) . Taken together, the results suggested that APCs acquire an immature phenotype in the presence of cerebral amyloidosis.
Accumulation of intracellular MHC-II in ArcAb brains
If APCs in ArcAb brains display an immature phenotype, they should accumulate MHC-II in intracellular compartments. To test this, we measured total (surface plus intracellular) MHC-II expression in mononuclear cells derived from the same samples. This analysis confirmed a significant increase in MHC-II-expressing cell numbers ( Fig. 6H and I) . In contrast to the reduced surface expression levels (Fig. 6F) we found an unchanged expression of total MHC-II in microglia (Fig. 6J) indicating an increase in intracellular MHC-II in ArcAb microglial cells. The accumulation of intracellular MHC-II was observed also in a second APP-tg model, the APP-PS1-dE9 ( Supplementary Fig. 3J ).
We next sought to confirm our flow-cytometry data using confocal microscopy. As expected, we detected several intensely labelled MHC-II + cells in 20-month-old ArcAb mice brains, while only few MHC-II-positive meningeal and perivascular cells were observed in non-tg brains (Fig. 6K, upper row) . When imaged at high magnification, MHC-II + cells from ArcAb mice harboured a distinct and intense intracellular vesicle-like staining (Fig. 6K , lower row, arrow-heads), as opposed to the diffuse and membrane-bound signals observed in perivascular MHC-II + cells from non-tg brains (Fig. 6K, lower row, arrows) . The vesicle-like MHC-II staining was consistent with an intracellular accumulation of MHC-II seen via flow-cytometry, and further supported the notion of an immature phenotype of APCs in ArcAb brains.
Loss of antigen-presenting cells at the choroid plexus of ArcAb mice
MHC-II expression was further analysed at the level of the blood-CSF-barrier in the CP, where mature DCs responsible for brain immune surveillance are known to reside (Colton, 2013; Anandasabapathy et al., 2011) .
Bona-fide DCs constituted up to 40% of the CD11b + CD45 hi population, with high MHC-II-expression levels comparable to splenic DCs ( Fig. 7A and B) . We found that choroid plexus-DCs (CP DCs) from ArcAb of 20-months of age were less frequent and exhibited lower MHC-II expression levels compared to age-matched non-tg littermates ( Fig. 7A and B) . The reduction in MHC-II expression at the CP, confirmed by immunohistochemistry (Fig. 7C) , further indicated low antigen-presentation in brains of ArcAb mice.
MHC-I up-regulation on brain-derived myeloid cells from ArcAb mice
To complete our characterisation of brain-derived antigen presenting cells in amyloid-burdened mice, we have assessed the expression of MHC-I on brain myeloid cells via flow-cytometry and confocal microscopy. For these studies we used 22-25 month-old ArcAb mice, since this model presented with robust infiltration of CD8 + T-cells as of 22 months of age.
The frequency of MHC-I-positive microglia and peripheryderived myeloid cells was significantly increased in ArcAb mice compared to aged-matched non-tg littermates ( Fig. 8A and B) , while it was unchanged in the amyloid-free cerebellum from the same mice (Fig. 8D) . In addition, MHC-I expression was significantly up-regulated on both microglial and other myeloid cells derived from cerebrum, but not cerebellum, of ArcAb mice ( Fig. 8B and C) . Confocal microscopy revealed strong MHC-I expression by perivascular Iba-1 positive cells in aged ArcAb mice (Fig. 8C) . Increased MHC-I expression at the perivascular sites might support antigen-specific recruitment of CD8 + T-cells into the brain parenchyma of ArcAb mice (Galea et al., 2007) .
Discussion
There is convincing evidence from pre-clinical, epidemiological and genetic studies that the immune system plays a crucial role in AD (Wyss-Coray and Rogers, 2012; International Genomics of Alzheimer's Disease and International Genomics of Alzheimer's Disease Consortium, 2015) . A decreased phagocytic activity of microglia due to chronic activation is currently regarded as the main cause of defective Ab clearance from AD brains (Krabbe et al., 2013; Hellwig et al., 2015) . Whether lymphocytes and Tcells in particular contribute to the immune dysfunction observed in AD is not known. Even though infiltrating T-cells in brains of AD patients have been consistently reported in the literature (Rogers et al., 1988; Itagaki et al., 1988; Togo et al., 2002) , comprehensive examination of their localisation and activation state is lacking, probably due to the low numbers of cells of interest in the postmortem brain specimens and the unsuitability of most samples for ex vivo flow-cytometry analysis.
On the other hand, tg mice, which reproduce severe AD-like cerebral amyloidosis, are the ideal tool to investigate the impact of amyloid on T-cell migration and function in brain. To this aim, we first examined the T-cell phenotype in our in-house model, the ArcAb mouse, which presents the advantage of harbouring abundant parenchymal plaques and CAA as of 12-months of age (Knobloch et al., 2007) ; subsequently, we have replicated our observations in at least one additional APP-tg model. Indeed, all APP-tg mice depositing cerebral amyloidosis reproduced the AD-like T-cell infiltration in brain. Infiltrating T-cells were observed in amyloid-burdened areas of three APP-tg mice models, independent of background, promoter used and of APP overexpression; in fact, it was neither observed in the plaquefree E22DAb mice (Fig. 3A) nor in systemic compartments (Fig. 1F) . No CD3 + T-cell was observed in RAG2-deficient APP-PS1-dE9 mice lacking mature B and T-cells, thus confirming the specificity of our technique ( Supplementary Fig. 1C ). The occurrence of brain infections that might explain the high CD3 + T-cell numbers was excluded via a specific microbiological examination. Hence, APP-tg mice are valuable models to study brain T-cells in the context of AD-like pathology. Taking advantage of APP-tg models, we have investigated the role of aging, CAA, parenchymal plaques and vascular alterations in T-cell infiltration, as well as obtained insights into their activation state. We found that aging per se contributed to T-cell infiltration; in fact, brain CD3 + T-cells were consistently detected in non-tg mice as of 12-months of age and were significantly increased at 22-24-compared to 12-month of age ( Fig. 1A and C) . However, in agreement with previous reports (Stichel and Luebbert, 2007 ) CD3 + T-cells were observed mostly in association with nervous fibres in non-tg mice (possibly due to white matter lesions described in older individuals (Maniega et al., 2015) ), while cortical areas were largely devoid of T-cell invasion. In contrast, APP-tg mice were readily distinguishable from control mice by the presence of more numerous infiltrating CD3 + T-cells, localised at the grey matter of all brain cortical areas examined (Fig. 1B-D) . Therefore, amyloid-dependent T-cell invasion was qualitatively and quantitatively different from the age-dependent T-cell occurrence.
Our observations in APP-tg models would support the notion that parenchymal amyloid causes brain T-cell invasion. Indeed, we found a significant correlation between CD3 + T-cell numbers and amyloid fractional area in ArcAb brains (Fig. 3B) , while the cerebellum of amyloid-depositing APP-tg mice ( Supplementary  Fig. 1A ) and the brains of E22DAb mice (Fig. 3A) , which are devoid of parenchymal amyloidosis, did not show invading CD3 + T-cells.
However, only a small fraction of infiltrating CD3 + T-cells observed in 15-month old ArcAb brains was amyloid-associated ( Fig. 3C-E) , similarly to previous observations (Jimenez et al., 2008) . The above results suggest that cerebral amyloid is necessary but not sufficient for T-cell invasion, which is likely caused by further downstream amyloid-mediated pathological events. APP-tg mice and ArcAb in particular (Merlini et al., 2011) display micro bleeds and loss of BBB integrity, which could contribute to T-cell invasion. We did not observe a physical association between T-cells and micro-haemorrhages detected with PB ( Fig. 4A-C) . Since PB reveals residual hemosiderin that has accumulated 6 to 10 days after the occurrence of a micro bleed (Koeppen et al., 1995) , T-cells might have already migrated in the parenchyma, explaining the lack of co-localisation. In this scenario, the densities of PB deposits and T-cells should correlate, even in the absence of direct spatial association. However, no such correlation was found (Fig. 4B) ; furthermore, no infiltrating B cells were detected (confirming (Rogers et al., 1988) ; data not shown), suggesting that physical BBB damage was not the cause of global lymphocyte extravasation. On the other hand, T-cell invasion in APP-tg brains was likely to be an active process relying on the interaction between endothelial adhesion molecules ICAM-1 and VCAM-1 and their cognate ligands leucocytes function-associated antigen (LFA)-1 and a4b1-integrin expressed on leucocytes (Engelhardt and Ransohoff, 2012) . In fact, we observed strong upregulation of endothelial adhesion molecules VCAM-1 and ICAM-1 in APP-tg mice brains areas, such as cerebral cortex and hippocampus, which are invaded by CD3 + T-cells ( Fig. 4D and Supplementary   Fig. 2B ), while no up-regulation was observed in cerebellum, an area spared by T-cell invasion ( Supplementary Figs. 1A and 2A) . Indeed increased LFA-1 ligand expression has been reported on AD brain-infiltrating T-cells (Togo et al., 2002) . The cause of VCAM-1 and ICAM-1 up-regulation in amyloid-burdened areas is currently unknown; however, soluble inflammatory cytokines such as TNF, IFN-c and IL-1b are likely to be the culprit. Such mediators, which have been shown to induce endothelial expression of both ICAM-1 (Pober, 1987) and VCAM-1 (Carlos et al., 1990) , are abundantly present in amyloid-burdened brains (Heneka et al., 2015) and are highly expressed by AD-derived brain endothelial cells (Grammas and Ovase, 2001 ).
In addition to the VCAM-1 and ICAM-1 up-regulation, we have also observed increased levels of MHC-I at perivascular sites in the ArcAb model. Since only activated antigen-specific CD8 + T-cells are able to cross the BBB (Galea et al., 2007) , this finding would support the notion that antigen-presentation at perivascular sites allows CD8 + T-cells infiltration into the brain parenchyma of ArcAb mice. Taken together, our results suggest that amyloid-induced endothelial cell activation might be responsible for T-cell infiltration in AD; further experiments are required to prove this possibility.
Infiltrating T-cells are ideally positioned to directly interact and potentially damage CNS-resident cells including neurons, astrocytes and microglia (Fig. 2D-F) . Our results however do not support a cytotoxic role for T-cells in AD. Infiltrating T-cells in ArcAb brains in fact did not actively proliferate nor displayed an effector phenotype (Fig. 5) ; in agreement with our results, differentiated CD8 + T-cells lacking cytolytic activity have been recently described in white matter of AD and other neurological disorders (Smolders et al., 2013) . The phenotype observed in APP-tg mice is rather consistent with an anergic or FoxP3 À regulatory T-cell type. Regulatory or anergic T-cells, while avoiding further neuronal damage, might be limiting the beneficial activation of peripheral macrophages and microglial cells. Lack of T-cell-derived IFN-c could impair microglia and macrophages phagocytosis (Schroder et al., 2004) . Indeed, IFN-c overexpression was shown to increase phagocytosis of Ab-plaques and promote macrophages infiltration in naïve (Chakrabarty et al., 2010) as well as Ab-immunized APP-tg mice (Monsonego et al., 2006) ; in the latter, however, clearance of Abplaques came at the cost of T-cell-mediated encephalitis, suggesting that a subtle temporal and regional regulation of IFN-c secretion is crucial for proper immune reaction in AD. Furthermore, regulatory or anergic T-cells might inhibit microglia phagocytic activity via the focal release of anti-inflammatory cytokines such as IL-10 and TGF-beta, both previously shown to modulate amyloid build-up in transgenic models (Town et al., 2008; Guillot-Sestier et al., 2015) . Supporting the possibility that the infiltrating T-cells play a regulatory role in amyloid-burdened brains, we have recently shown that RAG2-deficient APP-PS1-dE9 mice lacking mature B and Tcells display increased microglial phagocytic activity and lower Ab burden (Spani et al., 2015) . Furthermore, depletion of systemic regulatory T-cells was found to modulate microglia and promote amyloid clearance (Baruch et al., 2015) . The exact mechanism of T-cell mediated microglia responses remain to be elucidated.
At the moment it is not clear what causes the low T-cell proliferation and activation state in amyloid-burdened brains. The possibility that Ab itself directly inhibits T-cells has been previously proposed (Grant et al., 2012) and deserves further investigation. In addition, our results imply impaired antigen presentation activity in the presence of amyloidosis. Indeed, we found only few mature APCs in brain and CP samples of APP-tg mice (Fig. 6 , Supplementary Fig. 3 and Supplementary Table 1) and we provided evidence for immature APCs in amyloid-burdened brains (Fig. 6,  Supplementary Figs. 2 and 4 ). These observations are in line with previous reports indicating that exposure to Ab induces intracellular accumulation of MHC-II in human-derived DCs (Schmitt et al., 1997) and lowers MHC-II production in murine primary microglia (Butovsky et al., 2005) ; on the other hand, they are at odds with the well-known up-regulation of MHC-II in AD samples (Rogers et al., 1988; Parachikova et al., 2007) and tg models (Ferretti et al., 2011) . It is however possible that the up-regulation of MHC-II observed in previous studies was driven by intracellular MHC-II accumulated in immature APCs, which cannot be resolved via regular immunohistochemistry nor western blotting analysis. The lack of mature APCs in the cerebrum and CP together with the increase in immature APCs cumulatively indicates scarce antigen-presentation capability in APP-tg brains, which might contribute to low T-cell activation. Immature APCs, in addition to their role in limiting antigen presentation, might support a detrimental inflammatory state in amyloid-burdened brains, since high intracellular levels of MHC-II have been linked to TLR-triggered immune responses via Btk activation (Liu et al., 2011) .
Conclusions
Overall, our results suggest that amyloid deposition in brains is accompanied by low T-cell activation and down-regulation of antigen-presentation, supporting the concept of hyporesponsiveness of the immune system to Ab (Monsonego et al., 2001) . It is likely that Ab phagocytosis is an immunological silent phenomenon (Fitzner et al., 2011) , which limits the activation of the adaptive immune system to avoid detrimental autoimmunity. However, in the long term, microglial and macrophage capability to remove Ab might decline in the absence of T cell-derived stimulatory factors and/or in response to T-cell derived inhibiting signalling. Elucidating the mechanism responsible for T-cell hyporesponsiveness and its impact on microglia function could yield novel therapeutic targets to AD.
